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stabilizing a non-reactive conformation of the lung
cancer drug osimertinib†
D. Callegari, a K. E. Ranaghan, b C. J. Woods, b R. Minari, c M. Tiseo, c
M. Mor, a A. J. Mulhollandb and A. Lodola *a
Osimertinib is a third-generation inhibitor approved for the treatment of non-small cell lung cancer. It
overcomes resistance to ﬁrst-generation inhibitors by incorporating an acrylamide group which alkylates
Cys797 of EGFR T790M. The mutation of a residue in the P-loop (L718Q) was shown to cause resistance
to osimertinib, but the molecular mechanism of this process is unknown. Here, we investigated the
inhibitory process for EGFR T790M (susceptible to osimertinib) and EGFR T790M/L718Q (resistant to
osimertinib), by modelling the chemical step (i.e., alkylation of Cys797) using QM/MM simulations and the
recognition step by MD simulations coupled with free-energy calculations. The calculations indicate that
L718Q has a negligible impact on both the activation energy for Cys797 alkylation and the free-energy of
binding for the formation of the non-covalent complex. The results show that Gln718 aﬀects the
conformational space of the EGFR–osimertinib complex, stabilizing a conformation of acrylamide which
prevents reaction with Cys797.Introduction
Epidermal growth factor receptor (EGFR) is a transmembrane
protein which possesses an extracellular EGF binding domain
and an intracellular tyrosine kinase domain.1 EGFR activation
by its physiological ligand EGF leads to receptor dimerization
and phosphorylation, two events that trigger the activation of
signal transduction cascades promoting cell proliferation.2 In
non-small cell lung cancer (NSCLC), overexpression of EGFR or
hyper-activating mutations in its kinase domain have been
observed in at least 50% of cases.3 More than 90% of the known
kinase mutations occur as short in-frame deletions in exon 19
or as point mutations in exon 21, the latter resulting in arginine
replacing leucine at codon 858 (L858R).4 These mutations are
critical for NSCLC insurgence and progression as their presence
results in constitutive activation of EGFR regardless of the
presence of EGF.5 First-generation EGFR inhibitors (e.g., geti-
nib, 1, Scheme 1) are widely employed as rst-line therapy for
NSCLC with activating EGFR mutations (i.e. L858Rof Parma, Parma, Italy. E-mail: alessio.
ristol, UK
of Parma, Parma, Italy
(ESI) available: pKa shi for Cys797;
/MM calculations; analysis of the
alkylation; analysis of MD replicas;
of simulation of Cys797 alkylation;
each MD replica. See DOI:
Chemistry 2018substitutions in exon 21).6 Although patients show good
responses to the therapy, most of them acquire drug resistance
within 1 year treatment, which is driven in about 60% of cases
by an additional EGFR T790M point mutation7 occurring at the
gatekeeper position of the ATP binding site. The change in the
steric and lipophilic property of the gatekeeper residue is likely
to be responsible for the reduced inhibitory potency of rst-
generation EGFR inhibitors.8,9 The second generation of EGFR
inhibitors, such as afatinib (2, Scheme 1), demonstrated
promising activity against T790M-positive tumors in preclinical
models.10 Due to the presence of an acrylamide warheadScheme 1 Structures of relevant EGFR inhibitors.
Chem. Sci.
Fig. 1 Superposition of 3D models, derived from the X-ray structure
4ZAU.pdb,20 representing osimertinib in non-covalent complexes with
EGFR T790M (green carbon atoms) and EGFR T790M/L718Q mutants
(cyan carbon atoms), respectively.
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View Article Onlinecapable of alkylating Cys797,11 afatinib can circumvent ATP
competition and thus overcome the unfavorable eﬀect caused
by the presence of methionine at the gatekeeper position.11
Nevertheless, in the clinic afatinib showed dose-limiting toxicity
resulting from potent inhibition of the wild-type (wt) form of
EGFR.12
Osimertinib (3, Scheme 1)13 is a third-generation EGFR
inhibitor approved for patients aﬀected by metastatic EGFR
T790M mutation-positive NSCLC, who have progressed on or
aer the therapy with rst- and second-generation EGFR
inhibitors.14
Like other third-generation inhibitors, such as WZ4002 (4)
and rociletinib (5), osimertinib possesses a 2-aminopyrimidine
scaﬀold which confers selectivity for the oncogenic forms of
EGFR versus the wt, and an acrylamide group that alkylates
Cys797 ensuring the ability to potently inhibit EGFR also in the
presence of the T790M mutation.15
The development of novel forms of resistance is currently
limiting the clinical therapeutic benet of osimertinib.16 The
C797S mutation, which replaces the cysteine with the less
nucleophilic serine, has emerged as the main determinant of
resistance to third generation EGFR inhibitors.17 Other
mutations, i.e., L718Q occurring in the P-loop and L844V,
occurring in the ATP binding site, were initially reported to
confer resistance to pyrimidine-based inhibitors, including
WZ4002 and rociletinib, in vitro.18 Moderate activity on cells
harboring these mutations was maintained by osimertinib,
suggesting that it might be still clinically eﬀective in patients
harboring L718Q or L844V mutation. However, a cell prolif-
eration assay conducted in Ba/F3 cells expressing L858R/
T790M/L718Q EGFR mutant, showed that osimertinib was
considerably less potent (100-fold) at inhibiting cell growth
than in Ba/F3 cells expressing either L858R/T790M double
mutant or L858R/T790M/L844V triple mutant. This suggests
that L718Q mutation likely aﬀects the ability of osimertinib to
irreversibly inhibit EGFR. As a matter of fact, clinical resis-
tance to osimertinib has recently been reported in a NSCLC
patient expressing EGFR L858R/T790M who also acquired the
L718Q mutation.19 L718Q thus emerges as a mutation able to
reduce osimertinib potency in vitro and to confer NSCLC
resistance in vivo.19 Starting from the visual inspection of the
X-ray structure of EGFR–osimertinib complex,20 it has been
proposed that the replacement of a leucine with a glutamine at
the position 718 of EGFR could reduce the aﬃnity of EGFR for
osimertinib and/or hinder Cys797 alkylation by the acrylamide
warhead.19 Considering that Gln718 occupies a peripheral
position of the ATP binding site of EGFR (Fig. 1), the precise
role of Gln718 in reducing osimertinib activity remains largely
unexplained.
Computational simulation protocols able to rationalize the
eﬀects of a mutation in the binding site of EGFR have the
potential to contribute signicantly to anti-cancer drug
discovery:21 such methods should help in the design of novel
inhibitors able to circumvent mutations. Given the increasing
interest in and clinical importance of covalent inhibitors, there
is a particular need for methods able to analyze eﬀects of
mutation on covalent inhibition.Chem. Sci.In the present work, we investigate the impact of L718Q
mutation on the inhibitory activity of osimertinib by modelling
both its chemical step (i.e., Cys797 alkylation) and recognition
step (i.e. formation of the non-covalent, pre-reactive EGFR–
osimertinib complex). We started from X-ray20 derived models
of osimertinib in complex with EGFR T790M and EGFR T790M/
L718Q mutants. We assessed the inuence of the L718Q
mutation in EGFR inhibition, estimating for the two molecular
systems: (i) the preferred ionization state for Cys797; (ii) the
energetics for Cys797 alkylation; (iii) the free-energy of binding
for the formation of the non-covalent complex; (iv) the confor-
mational space explored by osimertinib within the two consid-
ered EGFR variants. An array of diverse and complementary
computational methods was applied. These include molecular
dynamics (MD) simulations,22 coupled with umbrella sampling
(US),23 hybrid quantum mechanics molecular mechanics (QM/
MM)24 and replica-exchange/thermodynamic integration
(RETI)25 approaches.Results and discussion
Ionization state of Cys797
The reactivity of cysteines with electrophilic compounds
depends rst of all on the protonation state of their thiol group,
as indicated by e.g., the pH dependence of the reaction rate for
covalent bond formation.26 EGFR has a solvent-exposed cysteine
(Cys797) that is the site of covalent modication by acrylamide-
containing irreversible EGFR inhibitors.6,27 The Cys797 thiol is
not only readily alkylated by Michael acceptors, but is also easily
transformed into sulfenic acid (i.e., Cys-S-OH) in the presence of
oxidative stimuli.27 This evidence to date supports the hypoth-
esis that the Cys797 thiol exists in the anionic form at physio-
logical pH. This could be due to the presence of an organized
microenvironment28 in EGFR able to stabilize its negative
charge.29 Furthermore, the Cys797 side chain makes contacts
with Asp800, with the sulfur atom at a short distance from one
of the oxygen of the carboxylic group, i.e., 3.3 A˚ in the EGFR–This journal is © The Royal Society of Chemistry 2018
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View Article Onlineosimertinib structure.20 Thus, the carboxylate function of
Asp800 is probably the natural acceptor of the Cys-SH proton
(Scheme 2).
Previous free-energy simulations have shown that, in the
presence of a N-(4-anilinoquinazolin-6-yl)acrylamide inhibitor,
Cys797–S/Asp800–COOH pair is signicantly more stable than
Cys797–SH/Asp800–COO.30 Moreover, titration experiments
on wt-EGFR showed that Cys797 has a pKa of 5.5,31 a value
signicantly lower than that of a free thiol in solution (z8.0),
and approaching that of a carboxylic acid. This supports the
computational nding that the most abundant protonation
state for this cysteine/aspartate pair of EGFR is Cys797–S/
Asp800–COOH. Therefore, this was the protonation state
employed in our models; we also investigated pKa shis of
Cys797 andmodeled the proton transfer between it and Asp800.
We began by evaluating the impact of the L718Q mutation
on the pKa of Cys797. With this aim, we built molecular models
of EGFR T790M and T790M/L718Q mutants using the X-ray
structure of osimertinib in non-covalent complex with wt-
EGFR.20 The models were equilibrated by molecular dynamics
(MD) simulations (see Experimental section for details). For
multiple snapshots taken from the MD simulations, pKa
calculations performed with PropKa (which uses an empirical
scoring function)32 and H++ (which solves the Poisson–Boltz-
mann equation)33 indicated that L718Q mutation has no
signicant eﬀect on the acidity of Cys797 thiol group, with
negligible pKa shis calculated by bothmethods (0.02 0.38 for
PropKa and 0.47  0.43 for H++, respectively; see also Table S1,
ESI†). It should be pointed out that theseDpKa values are simple
empirical estimates and thus they may suﬀer from limited
accuracy.
We next investigated if the L718Q mutation could aﬀect the
prototropic equilibrium of the Cys797/Asp800 pair. Applying
a SCC-DFTB/AMBER99SB QM/MM potential34 with umbrella
sampling (US) MD simulations,23 we calculated the free-energy
diﬀerence between the Cys797–S/Asp800–COOH and Cys797–
SH/Asp800–COO states. Starting from the molecular models of
osimertinib in complex with EGFR T790M or the EGFR T790M/
L718Q variant, the proton present on the carboxylic group of
Asp800 was moved toward the thiolate group of Cys797 in US
MD (see Experimental section).Scheme 2 Reaction mechanism of Cys797 alkylation for acrylamide
inhibitors of EGFR.
This journal is © The Royal Society of Chemistry 2018SCC-DFTB/AMBER99SB QM/MM US MD simulations
showed that the Cys797–S/Asp800–COOH state was of similar
stability to the Cys797–SH/Asp800–COO state for EGFR T790M
(estimated diﬀerence of 0.5  0.2 kcal mol1), while in the case
of EGFR T790M/L718Q, the Cys797–S/Asp800–COOH state was
more stable by 2.0  0.3 kcal mol1. It appears that the L718Q
mutation actually stabilizes the thiolate form of Cys797. It is
apparent that the eﬀects of this mutation on inhibition by osi-
mertinib alkylation are not caused by an increase in the pKa of
Cys797.Reaction energetics for Cys797 alkylation
Computational studies recently performed by us30 and others35
indicate that acrylamide-based inhibitors of EGFR alkylate
Cys797 by a direct addition mechanism in which the thiolate
group of Cys797 attacks the b carbon of the warhead, while the
carboxylic acid group of Asp800 protonates the a carbon,
leading to a stable 3-(alkylsulfanyl)propanamide adduct
(Scheme 2). Using this reaction scheme, we modelled the
Michael-type addition of Cys797 to osimertinib, for both EGFR
T790M and EGFR T790M/L718Q mutants.
To analyse the reaction energetics, the free-energy surface
(FES) of the direct addition mechanism was calculated from US
simulations at the SCC-DFTB/AMBER99SB level, using simple
reaction coordinates calculated from distances between the
reactive atoms: SCys797–Cbacrylamide distance modeled the
nucleophilic attack (event x), and the diﬀerence of distances
[(HAsp800–Caacrylamide)  (HAsp800–OAsp800)] described the
protonation at Ca of acrylamide (event y). While the SCC-DFTB
method is known to underestimate absolute barriers in many
cases, this approach has been satisfactorily applied to elucidate
the eﬀects of mutations on several enzyme-catalyzed reactions;
it provides useful and predictive relative barriers.36
The FES is a two-dimensional projection of a chemical
process that involves simultaneous changes in two coordinates.
Analysis of the FES is useful to explain how changes in the
microenvironment of the enzyme aﬀect the position and
geometry of the transition state (TS), and thus the energy barrier
of the investigated process.37 The SCC-DFTB/AMBER99SB FES
for the alkylation of Cys797 by osimertinib for EGFR T790M is
shown in Fig. 2A, and that for EGFR T790M/L718Q in Fig. 2B. In
both cases, the minimum free-energy path connecting reactants
(R, upper right corner) and the products (P, bottom le corner)
follows a diagonal pathway, indicating that nucleophilic attack
and protonation of the incipient carbanion species are tightly
coupled events. No carbanion/enolate species was identied as
a stable minimum, consistent with previous DFT calculations
on the addition of thiolates to acrylamides.30,35
The activation free-energy (DAact) at the SCC-DFTB/
AMBER99SB level of theory is 7.8  0.2 kcal mol1 for alkyl-
ation of EGFR T790M and of 8.1  0.2 kcal mol1 for alkylation
of EGFR T790M/L718Q. The barrier to the forward reaction
(formation of the covalent complex) is unaﬀected by the L718Q
mutation. The reaction free-energy (DAreac) is highly negative:
10.3  0.2 and 12.2  0.2 kcal mol1 for EGFR T790M and
EGFR T790M/L718Q, respectively, indicating that Cys797Chem. Sci.
Fig. 2 Free-energy surfaces for Cys797 alkylation by osimertinib in EGFR T790M (panel A) and in EGFR T790M/L718Q (panel B), calculated from
umbrella sampling simulations at the SCC-DFTB/AMBER99SB level of QM/MM theory. The reaction coordinates (nucleophilic attack and proton
transfer), are given in A˚. Free energies are given in kcal mol1, and the contour levels are set at 1 kcal mol1 while dashed-contour lines are set
every 4 kcal mol1.
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View Article Onlinealkylation by osimertinib is highly exergonic and thus a spon-
taneous process. The covalent adduct (products) is predicted to
be slightly more stable in the L718Q mutant, thus the barrier to
the reverse reaction is a little higher, but this is not expected to
be signicant as covalent inhibition is likely to be eﬀectively
irreversible. Overall, these results indicate that L718Q mutation
does not signicantly change the energetics of the alkylation.
Consistent with this nding, analysis of the geometries identi-
ed along the minimum free-energy path connecting R to P
indicates that L718Qmutation has a negligible impact on the TS
geometries obtained by US simulation (Table S2†).
The conformation adopted by the two conjugated double
bonds of the acrylamide fragment, which remained s-cis during
the entire alkylation process, is similar in the two reaction
paths. Further analysis of the minimum free-energy paths
(Fig. S1 and S2†), revealed that for both systems the key event of
the reaction was the nucleophilic attack of the Cys797 sulfur
atom on the acrylamide Cb, which required complete des-
olvation of the thiolate anion. In agreement with this nding,
structures of the TS for Cys797 alkylation of EGFR T790M, show
that the formation of S–Cb bond is quite advanced, with an
average (S–Cb) distance of 2.41  0.05 A˚. In contrast,Fig. 3 Representative structures of the TS for Cys797 alkylation in the
case of EGFR T790M (panel A, green carbon atoms) and EGFR T790M/
L718Q (panel B, cyan carbon atoms). Important distances (in A˚) are
shown by dashed magenta lines.
Chem. Sci.protonation of the Ca by Asp800 was not very advanced at the
TS, with an average H–Ca distance of 1.85  0.08 A˚ (Fig. 3A). In
the case of the EGFR T790M/L718Q variant, the TS structures
were slightly more advanced toward the products, as indicated
by S–Cb and H–Ca distances of 2.25  0.07 A˚ and 1.48  0.04 A˚,
respectively (Fig. 3B). These minor diﬀerences in the average
geometries of the TS for the direct addition mechanism explain
the negligible diﬀerence (0.3 kcal mol1) in the computed
activation free-energies DAact. Similar geometries were also
found for the products of the reaction.
The thioether adduct P was characterized by S–Cb and H–Ca
distances of 1.83  0.03 A˚ and 1.11  0.04 A˚, respectively for
EGFR T790M. The corresponding S–Cb and H–Ca distances
were 1.84  0.02 A˚ and 1.10  0.03 A˚ for the T790M/L718Q
variant, respectively. Thus, analysis of reaction paths shows
no signicant diﬀerence for the two EGFR mutants. All the
simulation evidence thus indicates that the L718Q mutation
does not reduce the reactivity of Cys797. It is important to note
that the starting point (reactant/non-covalent complex) for the
QM/MM calculations is a reactive conformation in which the
nucleophilic sulfur is in close proximity to the electrophile;
these simulations therefore do not address possible changes in
favored conformations in the non-covalent complex, which are
investigated below.Binding aﬃnity for the formation of osimertinib/EGFR
mutant non-covalent complexes
It has been recently proposed that the main eﬀect of the
replacement of Leu718 with Gln718 could be to disrupt the
benecial hydrophobic/steric interactions involving the
methoxyphenyl moiety38 of third generation EGFR inhibitors
(Fig. 1) and thus to hamper the formation of the non-covalent
complex through a signicant reduction of inhibitor aﬃnity.
We tested this hypothesis in silico by calculating the binding
free-energy (DAbind) of osimertinib for EGFR T790M and EGFR
T790M/L718Q, using the WaterSwap method39 in combination
with conventional MM MD simulations (see ExperimentalThis journal is © The Royal Society of Chemistry 2018
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View Article Onlinesection) performed using the AMBER99SB force eld.40 Water-
Swap estimatesDAbind using a replica-exchange thermodynamic
integration (RETI) algorithm along a reaction coordinate that
switches the ligand of interest with an equivalent volume of
water in the protein binding site.39 While this methodology
tends to overestimate the values of DAbind, it is able to capture
the eﬀect of mutations occurring in the binding site or in its
surroundings.41 To obtain a robust estimate of the binding free-
energy, ten independent WaterSwap calculations were per-
formed for each system i.e., starting from ten diﬀerent protein–
ligand structures taken from a 300 ns-long MD simulation.
WaterSwap simulations indicate (Table S3†) that osimertinib
has similar DAbind for EGFR T790M (34.9  0.7 kcal mol1)
and EGFR T790M/L718Q (34.8  1.9 kcal mol1) suggesting
that L718Q mutation does not signicantly aﬀect inhibitor
aﬃnity.Fig. 4 Deﬁnition of C1–C2–N1–C3 dihedral angle (panel A), and time
series for the S–Cb distance (blue line) and the C1–C2–N1–C3 dihedral
(red line) for EGFR T790M (panel B) and EGFR T790M/L718Q (panel C).Dynamics of osimertinib/EGFR mutant complexes
We nally investigated whether L718Q mutation aﬀects the
conformational space of osimertinib in the EGFR mutant–osi-
mertinib complexes. We performed extensive MD simulations
(4 independent replicas of 300 ns each) of osimertinib in non-
covalent complex with EGFR T790M and with EGFR T790M/
L718Q, using the AMBER99SB force eld40 (see Experimental
section for details). We then analyzed the simulations to assess
the inuence of the mutation on: (i) the binding of the 2-ami-
nopyrimidine scaﬀold of osimertinib to EGFR hinge region
within the ATP binding pocket, and (ii) the accommodation of
the acrylamide warhead.
Analysis of the trajectories indicated that L718Q mutation
has only a small eﬀect on the overall stability of the EGFR
protein. The root-mean square deviation (RMSD) of the back-
bone atoms for the rst set of 300 ns of MD simulation was of
1.60  0.49 A˚ for EGFR T790M and 2.20  0.31 A˚ for EGFR
T790M/L718Q. On the other hand, a signicant increase in the
exibility of the P-loop, i.e. the glycine-rich stretch where the
mutation is located, was observed when Leu718 was replaced by
Gln. Backbone-atom RMSD values were 1.99 0.49 A˚ and 3.50
0.85 A˚ for EGFR T790M and EGFR T790M/L718Q, respectively.
However, this increased exibility of the P-loop did not aﬀect
the overall stability of the EGFR–osimertinib complex: the
RMSD for the heterocyclic core of osimertinib was 1.13  0.32 A˚
for EGFR T790M and 1.62  0.49 A˚ for the EGFR T790M/L718Q
double mutant. Also, the distance of the key H-bond formed by
the N3-pyrimidine nitrogen of osimertinib and the backbone
N–H group of Met793 remains essentially the same i.e., 2.19 
0.21 A˚ for EGFR T790M and 2.11  0.15 A˚ for EGFR T790M/
L718Q double mutant. Similar behavior was observed in all
the simulations (see Fig. S3–S6, ESI†).
Further analysis of the MD simulations showed that the
presence of Gln instead of Leu did not dramatically alter the
average distance between Cys797 sulfur atom and the Cb of the
acrylamide, which moves from 4.9  0.90 A˚ for EGFR T790M to
6.0  1.0 A˚ for EGFR T790M/L718Q. However, detailed analysis
of the MD trajectories revealed that for EGFR T790M, the frac-
tion of reactive conformations, i.e. congurations in which theThis journal is © The Royal Society of Chemistry 2018nucleophile (Cys797 S) and electrophile (acrylamide Cb) are
separated by a distance smaller than the sum of their van der
Waals radii42 (i.e. 3.9 A˚ with the AMBER99SB force eld),
corresponds to 20.5% of structures, while in the case of the
EGFR T790M/L718Q double mutant, only 0.7% of structures
have Cys797 sulfur and acrylamide Cb at distances shorter than
3.9 A˚. Similar results were obtained in other MD replicas (Table
S4†). In these trajectories, the distribution of S–Cb distances
depends on the values assumed by the rotatable bond con-
necting the nitrogen of the acrylamide to the phenyl ring of
osimertinib (Fig. 4A). Analysis of the time series of S–Cb
distance and C1–C2–N1–C3 dihedral angle (which describes the
rotation along the above-mentioned C–N bond) indicates that
these two geometrical descriptors are highly correlated (Fig. 4).
When the S–Cb distance approached the critical value of 3.9 A˚,
the dihedral angle assumed values of 55  20, consistent
with the value observed in the X-ray structure, while when S–Cb
distance overcame the value of 5.5 A˚, a nearly 180 shi in the
C1–C2–N1–C3 dihedral angle was observed.
This trend was observed both in EGFR T790M (Fig. 4B) and
in EGFR T790M/L718Q (Fig. 4C). The time series reported in
Fig. 4B and C show the existence of two conformational states
for EGFR–osimertinib non-covalent complexes. Similar trendsChem. Sci.
Fig. 6 Representative geometry structures for EGFR T790M/L718Q–
osimertinib complexes taken from basin a* (green carbon atoms) and
b (cyan carbon atoms) of Fig. 5B. The H-bond involving Gln718 and the
acrylamide carbonyl is depicted with a dashed black line.
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View Article Onlinewere also observed when the MD simulations were replicated
(Fig. S7†).
Using MD simulations of the T790M and T790M/L718Q
systems, we calculated conformational FESs along S–Cb
distance and the C1–C2–N1–C3 dihedral angle. These FESs were
built by pooling the snapshots collected from four MD replicas
each of 300 ns (i.e. from a total of 1.2 ms MD simulations for
each system) and then performing a histogram analysis of the
conformational frequencies (see Experimental section). The
resulting FESs conrmed the existence of two basins (labelled
as a and b) for both EGFR T790M (Fig. 5A) and EGFR T790M/
L718Q (Fig. 5B) mutants.
In the case of EGFR T790M, the region a identies a well-
dened minimum centered at a S–Cb distance of 3.5 A˚ and
a C1–C2–N1–C3 dihedral angle of 55. This corresponds to the
geometry of the EGFR T790M–osimertinib complex belonging
to basin R of Fig. 2. Region a thus contains reactive confor-
mations, i.e., conformations extending from the ground state of
the complex that lie on the transition path leading to the
alkylation of Cys797. Region b identied a wider minimum
corresponding to unreactive conformations of the EGFR–osi-
mertinib complex, in which the S–Cb distance was dispersed
over a 4.5–6.5 A˚ interval due to a change in C1–C2–N1–C3 dihe-
dral angle, which adopted conformations in the range +100 to
+120. a and b possess nearly the same free-energy and thus
they can be regarded as equally populated conformational
states.
For EGFR T790M/L718Q, signicant changes were observed
in the positions of minima a and b, and in their relative pop-
ulations. Firstly, minimum a does not correspond to any reac-
tive conformations. Congurations in this area of the FES
feature a S–Cb distance approaching 4.5 A˚ and thus are hardly
capable of leading to Cys797 alkylation. Minimum b describes
unreactive conformations where the S–Cb distance is even
higher (5.5–7.0 A˚ range) while the C1–C2–N1–C3 dihedral angle
remains close to the interval ranging from +90 to +110, alreadyFig. 5 Free energy surfaces calculated from the frequency distribution of
of EGFR T790M (panel A) and EGFR T790M/L718Q (panel B) in non-co
basins in the space of S–Cb distance and C1–C2–N1–C3 dihedral angle; a
T790M/L718Q–osimertinib (which approximately corresponding to basin
at 0.25 kcal mol1 while dashed-contour lines are set every 1 kcal mol
Chem. Sci.observed for the unreactive basin of the T790M mutant.
Importantly, basin b represents the global minimum of the
computed FES for the EGFR T790M/L718Q system, being more
stable than basin a by nearly 1 kcal mol1. It is still possible to
identify reactive geometries for the EGFR T790M/L718Q
mutant. These conformations are situated on a region of the
FES, labelled with a* (Fig. 5B), which does not correspond to
a free-energy minimum. a* is higher in energy than basin b by
z3 kcal mol1. The stabilization of basin b compared to a and
a* in the L718Q mutant arises from a H-bond between the side
chain of Gln718 and the carbonyl oxygen of the acrylamide
group of osimertinib (Fig. 6). The hydrogen bond is maintained
for a signicant part of the MD simulations. Comparison of the
time evolution for the H-bond distance, the C1–C2–N1–C3
dihedral angle (Fig. S8†) and the S–Cb distance (Fig. S9†),conformations obtained from four independent 300 ns MD simulations
valent complex with osimertinib. a and b identify two conformational
* represents, in panel B, the region of reactive conformations for EGFR
a in A). Free energies are given in kcal mol1, the contour levels are set
1 with an additional line at 3.5 kcal mol1.
This journal is © The Royal Society of Chemistry 2018
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View Article Onlineindicates that formation of this H-bond is the key driver leading
to stabilization of the unreactive states for EGFR T790M/L718Q–
osimertinib complex. The hydrogen bond between the side-
chain of Gln718 and the carbonyl oxygen of acrylamide drives
the transition of the C1–C2–N1–C3 dihedral angle and places the
electrophile Cb far away from the Cys797 thiolate. This H-bond
mediated stabilization of a non-reactive conformation; this
conformational change of the non-covalent complex will
hamper the formation of a covalent bond and thus appears to
be the central cause of how the T790M/L718Q mutant escapes
irreversible inhibition by osimertinib. These conclusions are
supported by all the other MD replicas (which are reported in
Fig. S8 and S9 of the ESI†).
Conclusions
The clinical use of third-generation EGFR inhibitors is revealing
the insurgence of novel mutations which confer to lung cancer
cells the ability to escape EGFR inhibition. Among recently re-
ported mutations, L718Q has emerged as an intriguing muta-
tion considering that this occurs in a region of EGFR peripheral
to the ATP binding site and that its eﬀect is not obvious (in
contrast e.g. to the C797S mutation). Here, a multilevel
computational approach has provided evidence that L718Q
mutation does not aﬀect the ionization state of Cys797 (the
intrinsic reactivity of Cys797 is not reduced) nor the activation
free-energy for the direct addition of acrylamide to the a,b
double bond. Free-energy calculations, performed with a replica
exchange-thermodynamic integration method, indicate that
L718Q mutation does not aﬀect the aﬃnity of osimertinib for
the EGFR active site. On the other hand, simulations show that
Gln718, through an H-bond with the acrylamide warhead,
stabilizes a specic conformation of osimertinib in which the
electrophilic Cb of its acrylamide substituent is kept away from
the Cys797 thiolate. This conformation hampers Cys797 alkyl-
ation and may thus favor the displacement of osimertinib from
EGFR by ATP, which is present in cells at high concentrations.11
This global picture rationalizes the poor inhibitory activity of
osimertinib in Ba/F3 cells harboring the L718Q mutation18 and
the lack of therapeutic activity of osimertinib in patients who
have acquired this mutation.19 We believe that the protocol
described here represents a viable and generalizable strategy to
investigate in silico the eﬀects of mutations on covalent inhibi-
tion. This requires consideration of several distinct factors: (i)
evaluation of the ionization state of the nucleophile; (ii) estima-
tion of the free-energy barrier for covalent adduct formation; (iii)
binding aﬃnity for the formation of the non-covalent complex;
(iv) mutual orientation of the reactants within the target active
site. Moreover, our conclusion about the conformational selec-
tion induced by L718Q mutation should be useful for the design
of new EGFR inhibitors overcoming drug resistance.
Experimental
Model building and equilibration
EGFR T790M and EGFR T790M/L718Q in complex with osi-
mertinib were built starting from the crystal structure of theThis journal is © The Royal Society of Chemistry 2018non-covalent complex between wt EGFR and osimertinib
(4ZAU.pdb),20 using the LEaP program available in AMBER 16
(AMBER 2016, University of California, San Francisco, CA). The
resulting complexes were immersed in a box of TIP3P water
molecules43 and neutralized with 3 chloride ions. The total
system size was 46 936 atoms (14122 TIP3P waters) in the case
of the EGFR T790M–osimertinib complex and 46 283 atoms in
the case of the EGFR T790M/L718Q–osimertinib complex
(13905 waters). Solvated complexes were energy-minimized,
gradually heated to 300 K in NVT ensemble and equilibrated
at pressure of 1 atm in NPT ensemble. These systems were then
submitted to a short MD simulation (10 ns) in the NVT
ensemble. In all these simulations, the AMBER99SB force eld
was applied to describe protein atoms while the generalized
AMBER force eld (GAFF)44 was employed to describe osi-
mertinib. The pmemd.cuda code of AMBER16 was used to
perform these simulations on NVIDIA K20 GPU cards. Full
electrostatic and van der Waals interactions were computed
within a cutoﬀ of 10 A˚ and long range electrostatic interactions
were treated using the particle mesh Ewald (PME) with 128 
128  128 grid points. Covalent bonds involving hydrogens
were constrained using the SHAKE function, allowing the use of
a time step of 2 fs. The structures extracted from these MD
trajectories (snapshots) were employed to estimate pKa for
Cys797, for QM/MM simulations, and to perform further MD
simulations (see below).
pKa calculations
Ten equally spaced snapshots were taken from the 10 ns MD
trajectories for EGFR T790M–osimertinib and EGFR T790M/
L718Q–osimertinib complexes. The structures were exported as
PDB les and submitted to pKa calculations using Propka3.0
(ref. 32) and H++ (ref. 33) soware using default settings.
Individual DpKa values were calculated as Cys797 pKa of EGFR
T790M minus Cys797 pKa of EGFR T790M/L718Q, while the
nal values reported in main text resulted from their average.
The uncertainty of DpKa was estimated calculating the standard
error of the mean (SEM). Absolute pKa values are reported in
Table S1 in the ESI.†
Application of the QM/MM potential
QM/MM has been extensively applied to study reaction mech-
anisms in condensed phase, including enzymes. This approach
has the advantage that large systems can be investigated with
a reasonable computational cost. The central idea behind the
QM/MM approach is the partitioning of the system of interest
into two interacting regions: (i) a small QM region, where the
chemical bond breaking and forming take place and (ii) a large
MM region surrounding the QM atoms. Here, we applied the
self-consistent charge-density functional tight binding (SCC-
DFTB)45 model to describe the QM region and the AMBER99SB
force eld to describe the MM region. The SCC-DFTB approach
is based on the second-order expansion of the total DFT energy
with respect to the charge-density variation. Hybrid QM/MM
potentials derived from the SCC-DFTB theory have been
widely applied to enzyme-catalyzed reactions and oen giveChem. Sci.
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View Article Onlinereasonable descriptions of reaction geometries and ener-
getics.46 In the EGFR–osimertinib complexes, side chain atoms
of Cys797, Asp800 and the acrylamide portion of the inhibitor
were treated with the SCC-DFTB method with dispersion
correction. The resulting QM system was composed of 23
atoms, including three link atoms placed along the C–C bond
connecting Cb of the amino acids to their backbone Ca and
along the C–N bond connecting the acrylamide nitrogen to the
phenyl ring of osimertinib. The adjust_q function was applied
to conserve the charge of the systems.
US simulation for Cys797 deprotonation by Asp800
A set of US simulations was performed by adding a spring
constant of k ¼ 100 kcal mol1 A˚2 along the diﬀerence of
distances (HAsp800–SCys797)  (HAsp800–OAsp800). This diﬀerence
was named as reaction coordinate r and was sampled from 1 to
1 A˚ with a step-size of 0.1 A˚, giving a total of 21 windows. For
each window, 50 ps of QM/MM MD simulation at 300 K in NVT
conditions were performed for a total of 1 ns of simulation,
using the sander.MPI module of AMBER16. All the atoms of the
system (including hydrogens) were allowed to move during the
simulations, and a time step of 0.2 fs was used to integrate the
equation of motion. The PME approach was used to treat the
QM/MM long-range electrostatic interactions. The unbiased
FES was calculated by using the weighted histogram analysis
method (WHAM).47 Convergence of the simulations was evalu-
ated calculating the diﬀerence in the free-energy between
Cys797–S/Asp800–COOH and Cys797–SH/Asp800–COO states
as function of the simulation time. This diﬀerence reached
a stable value aer 40 ps of simulation for each window
(Fig. S10†). The free-energy diﬀerence between the two ioniza-
tion states was calculated at diﬀerent simulation time once
convergence was achieved i.e., aer 40, 45 and 50 ps. The nal
energies reported here represent mean values  standard
deviation.
US simulation for Cys797 alkylation
USMD simulations were carried out adding a spring constant of
100 kcal mol1 A˚2 along the reaction coordinate x, described
by the SCys797–Cbacrylamide distance, and reaction coordinate y,
described by the diﬀerence of distances (HAsp800–Caacrylamide) 
(HAsp800–OAsp800). Coordinate x was sampled from 3.6 to 1.8 A˚
with a step-size of 0.1 A˚ for a total of 19 windows while coor-
dinate y was sampled from 2.8 to2.0 A˚ with a step-size of 0.2 A˚
for a total of 26 windows. Overall the simulated grid is
composed of 494 windows. For each one, 50 ps of QM/MM MD
simulation at 300 K in NVT conditions were performed for
a total of 24.7 ns. The same settings described for Cys797–
Asp800 proton transfer were applied. The presence of a normal
distribution of the sampled data along x and y was veried
within each simulated window. The employed spring constant
allowed a satisfactory overlapping of the sampled windows,
which is critical to obtain a reliable and continuous FES per-
formed for each umbrella. The unbiased FES was calculated by
using the weighted histogram analysis method (WHAM).47
Convergence of the simulations was evaluated calculating theChem. Sci.DAact and DAreac as functions of the simulations time. These two
outputs reached stable values within 30 ps of QM/MM MD
simulation for each window. Average values and standard
deviations reported in the main text were calculated from data
collected at 30, 40 and 50 ps of simulation for each window.
This was the case of both EGFR–osimertinib complexes
(Fig. S11†). The US simulations were also repeated to evaluate
their reproducibility (Fig. S12†).WaterSwap calculations
From a 300 ns trajectory for the EGFR T790M–osimertinib and
EGFR T790M/L718Q–osimertinib complexes, 10 equally spaced
snapshots were selected and employed for WaterSwap calcula-
tions. Binding free energies were calculated using replica-
exchange thermodynamic integration over 16l windows
(0.005, 0.071, 0.137, 0.203, 0.269, 0.335, 0.401, 0.467, 0.533,
0.599, 0.665, 0.731, 0.797, 0.863, 0.929, 0.995) over the Water-
Swap reaction coordinate. 30 million Monte Carlo moves were
performed for each window, with the free-energy gradient
averaged over the last 20 million steps. Monte Carlo sampling
involved protein residues and water molecules within 15 A˚ of
the center of osimertinib. Simulations used the set A so-core
parameters described in ref. 39, with a 15 A˚ coulomb and
Lennard Jones non-bonded cutoﬀ. This shied cutoﬀ was used
to better account for long-range electrostatics.
DAbind values reported here are mean values  the standard
error of the mean, as obtained from 10 independent simulation
runs.Unbiased MD simulations and free energy calculations
Starting from equilibrated systems of EGFR T790M–osimertinib
and EGFR T790M/L718Q–osimertinib complexes we performed
4 runs of 300 ns-long MD simulations at 300 K in NVT condi-
tions using the settings described above. Snapshots collected
from MD trajectories (30 000 for each replica, for a total of
120 000 for each system) were employed to build the 2D-free-
energy surfaces in the space of S–Cb distance and C1–C2–N1–
C3 dihedral angle. The free-energy along these variables was
computed applying the following equation:
A(r) ¼ kBT ln P(r)
where P is the probability distribution, kB is the Boltzmann
constant, and T is the simulation temperature. The 2D distri-
bution function P(r) was obtained performing a histogram
analysis of conformational frequencies with the cpptraj
module48 implemented in AMBER16. Snapshots were separated
into classes based on the values of the S–Cb distance and C1–
C2–N1–C3 dihedral angle. S–Cb distance ranged from 2.5 to 9.5 A˚
with a class width of 0.1 A˚, while the C1–C2–N1–C3 dihedral
angle ranged from 160 to +160 with a class width of 15.
FESs in the space of S–Cb distance and C1–C2–N1–C3 dihedral
angle for each replica are reported for EGFR T790M–osimerti-
nib and EGFR T790M/L718Q–osimertinib complexes in Fig. S13
and S14, respectively of the ESI† section.This journal is © The Royal Society of Chemistry 2018
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